Subjective Assessment of Spatial Orientation Abilities in Alzheimer's Disease (ESCAPE-AD)
Evaluation Subjective Des CApacités d'Orientation sPatialE Dans la mAladie D'Alzheimer
Difficulty orienting oneself and finding one's way around the environment, also known as "topographical disorientation" (TD) or "spatial disorientation" (SD), is a common and often early symptom of Alzheimer's disease (AD) that affects people's independence and well-being. Being able to identify it is therefore crucial in order to provide appropriate support.
It cannot be assessed using conventional psychometric tests due to its low ecological validity. Several subjective assessment scales have been created to screen for SD "spatial disorientation" and assess its functional and psychological impact. However, none of these scales have been translated and validated in French. As a result, DS is not assessed in routine clinical practice.
Among these scales, the Wayfinding Questionnaire (WQ) explores three dimensions: spatial orientation, distance estimation, and spatial anxiety. This questionnaire has undergone psychometric validation studies in its original Dutch version for a population with mild post-stroke , and norms for the general population have been published.
Our team translated this questionnaire into French (i.e., "Questionnaire d'Orientation Spatiale" (QOS)) and adapted it cross-culturally to preserve the qualities of the measurement. A "Caregiver" version was also created, taking into account the anosognosia known to occur in AD. Primary Objective : Evaluate the psychometric properties of the Spatial Orientation Questionnaire (SOSQ) (i.e., the French translation and adaptation of the Wayfinding Questionnaire) in assessing spatial orientation disorders in patients with Alzheimer's disease, in both its "patient" and "caregiver" versions. Secondary objective : Evaluate the acceptability of the Spatial Orientation Questionnaire (SOC) in its "patient" and "caregiver" versions.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: EL AKHDAR Hajar, Master Science
- Número de telefone: 0383153596
- E-mail: h.elakhdar@chru-nancy.fr
Locais de estudo
-
-
-
Nancy, França, 54500
- CHRU (Centre Hospitalier Régionale Universitaire) Nancy
-
Contato:
- Hajar EL AKHDAR
- Número de telefone: +33 3 83 15 35 96
- E-mail: h.elakhdar@chru-nancy.fr
-
Investigador principal:
- Thérèse JONVEAUX, Dr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
For all subjects :
- Native French speakers
- Independent mobility: (minimum mobility range of 3 (i.e., neighborhood) on the LSA-F assessment of the mobility zone scale)
- Person affiliated with a social security system or beneficiary of such a system
Patients (Subgroup A1) and healthy control subjects (Group C):
- Individuals who have received complete information about the clinical research organization and have signed their written informed consent
- Patients (Subgroups A2 and A3) and Companions (Group B) Individuals who have received complete information about the clinical research and have agreed to participate
Patients (group A):
- Aged 55 to 85
- Diagnosis of probable Alzheimer's disease (NINCDR-ADRDA diagnostic criteria)
- Score of 4 or less on the Hachinski Ischemic Scale
- Score of 20 or higher on the Folstein MMSE (Mini Mental State Examination)
- In the case of specific treatment for Alzheimer's disease (anticholinesterase and memantine treatments), treatment stability for > 15 days
- Able to walk independently, i.e., without assistance, whether human or technical, except for a simple cane
Caregivers (group B):
- Caregivers of a person with dementia included in group A, with regular contact (at least 10 hours per week, spread over a minimum of 3 times per week)
- Healthy control subjects (group C):
- Aged 55 to 85
- Able to walk independently, i.e., without assistance, whether human or technical, except for a single cane
- Normal performance on the Folstein Mini-Mental State Examination (MMSE), according to GRECO (Cognitive Assessment Task Force) standards
Exclusion Criteria:
For all subjects:
- Adults subject to legal protection measures (guardianship, curatorship, judicial protection)
- Adults unable to give their consent
- Persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1.
- Persons capable of giving consent but unable to read French
- Persons capable of giving consent but unable to write
- One of the members of the patient/caregiver dyad refusing to participate in the study.
Patients (subgroup A1) and healthy control subjects (group C):
- Sensory or phasic deficit interfering with the task.
- History of moderate or severe head trauma (with loss of consciousness).
- Change in psychotropic treatment less than 48 hours before the tests
- Chronic alcoholism
- Severe depression (score greater than or equal to 10 on the GDS-15 Geriatric Depression Scale)
- Presence of other clinically significant psychiatric or neurological conditions (except Alzheimer disease for case subjects)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Patients Group
Patients with Alzheimer disease
|
French version of the wayfinding questionnaire
|
|
Accompanying persons
Relatives (friends or family) of patients with alzheimer disease
|
French version of the wayfinding questionnaire
|
|
Control arm
Healthy participants
|
French version of the wayfinding questionnaire
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
French version of the QOS Score
Prazo: Baseline and between 30 and 90 days after baseline for groups A1, A2, A3, B1 and B2
|
There are three sub-scores in total :
For these three sub-scores, a high score indicates a good level of spatial orientation. |
Baseline and between 30 and 90 days after baseline for groups A1, A2, A3, B1 and B2
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91. doi: 10.1097/00007632-200012150-00014. No abstract available.
- Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993 Dec;46(12):1417-32. doi: 10.1016/0895-4356(93)90142-n.
- de Rooij NK, Claessen MHG, van der Ham IJM, Post MWM, Visser-Meily JMA. The Wayfinding Questionnaire: A clinically useful self-report instrument to identify navigation complaints in stroke patients. Neuropsychol Rehabil. 2019 Aug;29(7):1042-1061. doi: 10.1080/09602011.2017.1347098. Epub 2017 Jul 18.
- Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. J Clin Epidemiol. 2015 Apr;68(4):435-41. doi: 10.1016/j.jclinepi.2014.11.021. Epub 2014 Dec 17.
- van der Ham IJM, Claessen MHG. A clinical guide to assessment of navigation impairment: Standardized subjective and objective instruments and normative data. J Clin Exp Neuropsychol. 2022 Sep;44(7):487-498. doi: 10.1080/13803395.2022.2123895. Epub 2022 Sep 21.
- van der Ham IJ, Kant N, Postma A, Visser-Meily JM. Is navigation ability a problem in mild stroke patients? Insights from self-reported navigation measures. J Rehabil Med. 2013 May;45(5):429-33. doi: 10.2340/16501977-1139.
- Claessen MHG, Visser-Meily JMA, de Rooij NK, Postma A, van der Ham IJM. The Wayfinding Questionnaire as a Self-report Screening Instrument for Navigation-related Complaints After Stroke: Internal Validity in Healthy Respondents and Chronic Mild Stroke Patients. Arch Clin Neuropsychol. 2016 Dec 1;31(8):839-854. doi: 10.1093/arclin/acw044.
- Hegarty, M., Montello, D. R., Richardson, A. E., Ishikawa, T., & Lovelace, K. (2006). Spatial abilities at different scales : Individual differences in aptitude-test performance and spatial-layout learning. Intelligence, 34(2), 151-176. https://doi.org/10.1016/j.intell.2005.09.005
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2019PI271
- N°ID-RCB : 2025-A00441-48 (Outro identificador: ANSM (The National Agency for Drug and Health Product Safety))
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .